Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06620042 · ClinicalTrials.gov registry record · Phase 2
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
A Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression, sponsored by Brian Barnett.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06620042 is a Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression that has completed, run by Brian Barnett. The registered enrollment target is 20 participants, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06620042, a Phase 2 study of Bipolar Depression and Treatment-resistant Bipolar Depression, has completed, sponsored by Brian Barnett.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.
Conditions Studied
Interventions
- DRUG Ketamine
- OTHER Functional magnetic resonance imaging (fMRI)
Study Locations (2)
Ohio
- Cleveland Clinic Lutheran Hospital - Cleveland
- Cleveland Clinic Lutheran Hospital - Ohio City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06620042
The ClinicalTrials.gov registry entry for NCT06620042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The listed sponsor is Brian Barnett, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bipolar Depression appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT06620042 reports 2 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06620042 about?
NCT06620042 is a clinical study titled "FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression". This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI.
What is the current status of trial NCT06620042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-11-12. Estimated completion is 2025-10-31.
What conditions does trial NCT06620042 study?
This clinical trial studies the following conditions: Bipolar Depression, Treatment-resistant Bipolar Depression.
What interventions are being tested in trial NCT06620042?
The interventions under investigation include: Ketamine (DRUG), Functional magnetic resonance imaging (fMRI) (OTHER).
Who is sponsoring clinical trial NCT06620042?
This trial is sponsored by Brian Barnett, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06620042 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
COMPLETED · Phase 2
-
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
RECRUITING · Early Phase 1
-
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
RECRUITING · Phase 3
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
Ketogenic Intervention for Bipolar Depression
RECRUITING · NA
-
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.